Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus

Abstract

Background Erectile dysfunction is a common multi-factorial complication of diabetes mellitus. Numerous strategies have been tried to overcome this diabetic complication. In recent years, phosphodiesterase type 5 (PDE-5) inhibitors have been introduced in the management of erectile dysfunction. Objectives The objective of this review was to assess the effect of PDE-5 inhibitors on the management of erectile dysfunction in diabetic men. Search methods Studies were obtained from computerised searches of MEDLINE, EMBASE and The Cochrane Library. Selection criteria Randomised controlled trials, in which treatment with PDE-5 inhibitors was compared to control, in diabetic patients with erectile dysfunction. Data collection and analysis Two reviewers independently extracted data and assessed trial quality. Main results Eight randomised controlled trials were identified. A total 976 men were allocated to receive a PDE-5 inhibitor and 741 were randomised to the control groups. Overall, 80% of the participants suffered from type 2 diabetes mellitus. The weighted mean difference (WMD) for the International Index of Erectile Function (IIEF) questions 3 and 4 (frequency of penetration during and maintaining erection to completion of intercourse) was 0.9 (95% CI 0.8 to 1.1) and 1.1 (95% CI 1.0 to 1.2) at the end of the study period, in favour of the intervention group. The WMD for the IIEF erectile dysfunction domain at the end of the study period was 6.6 (95% CI 5.2 to 7.9) in favour of the PDE-5 inhibitors arm. The relative risk (RR) for answering "yes" to a global efficacy question ("did the treatment improve your erections?") was 3.8 (CI 95% 3.1 to 4.5) in the PDE-5 inhibitors compared with the control arm. The WMD between the percentage of successful attempts in the PDE-5 inhibitors and in the control arm was 26.7 (95% CI 23.1 to 30.3). Mortality was not reported in any of the included trials. Adverse cardiovascular effects were reported in one study. Headache was the most frequent adverse event reported, flushing was the second most common event, with upper respiratory tract complaints and flu like syndromes, dyspepsia, myalgia, abnormal vision and back pain also reported in a descending order of frequency. The overall risk ratio for developing any adverse reaction was 4.8 (CI 95% 3.74 to 6.16) in the PDE-5 inhibitors arm as compared to the control. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus (Review)

Diabetes and sexual dysfunction: current perspectives

“…These drugs differ in their time to onset and in their duration of action, but they show the same efficacy and safety profile. All of them have shown their efficacy in diabetic patients,84 although it has been reported that diabetic men with ED are less responsive to PDE5 inhibitors when compared with nondiabetic men with ED 85. A randomized, placebo controlled trial, involving 268 diabetic men with ED, reported improved erections in 56% of patients taking sildenafil in a dose-dependent manner, compared with 10% of those in the control group 86.…”

Sexual dysfunction in men with type 2 diabetes

“…All of them have shown their efficacy in diabetic patients 100. The three drugs differ from each other in time to onset and duration of action, but have similar efficacy and safety profiles.…”

Levels of Soluble Advanced Glycation End Product-Receptors and Other Soluble Serum Markers as Indicators of Diabetic Neuropathy in the Foot

“…2 Approximately 50% of diabetics may eventually develop nerve damage. 3 Moreover, depending on affected nerves, symptoms of DN can range from pain and numbness in extremities to digestive system, urinary tract, blood vessels, and heart problems. 4 Pathogenic mechanisms linking hyperglycemia with DN include increased polyol pathway flux, protein kinase C activation, increased hexosamine pathway flux, enhanced formation of reactive oxygen species, increased production of vascular endothelial growth factor, and altered generation of endothelial nitric oxide (NO).…”